Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Brain Injuries, Traumatic, Spinal Cord Trauma, Intracranial Neoplasm
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Frown Lines
Interventions: Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"; Biological
Lead sponsor: Croma-Pharma GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Santa Monica, California • Coral Gables, Florida

Conditions: HIV Infection
Interventions: LPV/rtv, TMC114/rtv; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 39
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 36 more

Conditions: Asthma
Interventions: AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 21
States / cities: Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more

Conditions: Type 2 Diabetes Mellitus, Insomnia, Sleep Disorder, Inflammation
Interventions: Suvorexant, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: ECRB Tendinopathy
Interventions: Semiconductor Embedded Therapeutic Arm Sleeves, Placebo Arm Sleeves, Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections; Device · Other
Lead sponsor: INCREDIWEAR HOLDINGS, INC.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Abdominal Pain
Interventions: IBS-PPSM intervention; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Pain
Interventions: IV ibuprofen, Ketorolac; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Fort Lauderdale, Florida • Chicago, Illinois • Tupelo, Mississippi + 1 more

Conditions: Chronic Kidney Disease, Hypertension
Interventions: Dietary intake of potassium; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diet, Healthy, Diet Habit, Disease, Chronic, Health Behavior, Rural Health
Interventions: The UnProcessed Pantry Project (UP3); Behavioral
Lead sponsor: Montana State University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Osteoarthritis, Knee
Interventions: Amniotic Fluid, Saline Placebo; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Birmingham, Alabama • Atlanta, Georgia • Des Plaines, Illinois + 1 more

Conditions: Type 2 Diabetes
Interventions: Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 118
States / cities: Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more

Conditions: Infertility
Interventions: MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL, MENOPUR powder and solvent for solution for injection, 75 IU, Placebo (for MENOPUR solution for injection in pre-filled pen), Placebo (for MENOPUR powder and solvent for solution for injection); Drug · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 20
States / cities: Tempe, Arizona • San Diego, California • Farmington, Connecticut + 17 more

Conditions: Type1 Diabetes Mellitus
Interventions: Aspart; Drug
Lead sponsor: Mountain Diabetes and Endocrine Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Asheville, North Carolina

Conditions: Netherton Syndrome
Interventions: QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID; Drug
Lead sponsor: Quoin Pharmaceuticals; Industry
Eligibility: 14 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more

Conditions: Spinal Cord Injury Cervical, Stroke
Interventions: Motion and Emg Control; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 16 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Plaque, Dental, Gingivitis
Interventions: Colgate SNaP Total 10/10, 1.5 Taurate, Colgate Great Regular Flavor Toothpaste, Flat Trimmed Extra Clean TB; Drug · Other
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Costa Mesa, California

Conditions: Nondependent Opioid Abuse, Episodic
Interventions: Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Gait, Balance, Biomechanical Data, Postural Control, Locomotion
Interventions: Sensor-enabled Athletic X Ankle Brace (sXAB); Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Low Back Pain
Interventions: Mindfulness Meditation, Health Education; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Exenatide once weekly suspension, Exenatide twice daily; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 58
States / cities: Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more

Conditions: Any Condition Requiring Vulvar Biopsy
Interventions: EMLA, Lidocaine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Osteoarthritis, Knee Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions: Exercise for Knee Osteoarthritis Recommendations (Control group), Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking), Exercise for Knee Osteoarthritis - (Aquatic Walking); Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 50 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Lakewood, Colorado • Maitland, Florida • Naples, Florida + 6 more

Search by objective public record fields.

Characterization of Human Autoantibody Titers After Central Nervous System Insult

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy

Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain

Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery

Potassium Intake in Patients With Chronic Kidney Disease

The UnProcessed Pantry Project (UP3)

Protocol for the Clinical Evaluation of Lyophilized Amniotic Fluid in the Treatment of Knee Osteoarthritis

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

BoMI for Muscle Control

To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis.

Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

Sensor Ankle Brace for Special Operations Rehabilitation - Phase 1

Aging Successfully With Pain

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

Pain Perception During Vulvar Biopsy

Impact of Different Exercise Programs on Knee OA

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors